Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Crispr Therapeutics AG (CRSP)

489 + Investors. Track Smart Money conviction in CRSP. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +7
Streak
4Q ▲
Buyers last Q
57%

Smart Money Signals — CRSP

Based on 492 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added CRSP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
492 hedge funds hold CRSP right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+103 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 57% buying

270 buying200 selling
Last quarter: 270 funds bought or added vs 200 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-14 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 109 → 79 → 97 → 83. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

55% of holders stayed for 2+ years

■ 55% conviction (2yr+) ■ 23% medium ■ 22% new
269 out of 492 hedge funds have held CRSP for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~83 new funds/quarter

55 → 109 → 79 → 97 → 83 new funds/Q
New funds entering each quarter: 109 → 79 → 97 → 83. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Deep conviction — 62% of holders stayed 2+ years

■ 62% veterans ■ 10% 1-2yr ■ 28% new
Of 520 current holders: 323 (62%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds
55 of 492 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CRSP

In 2026 Q1, 270 hedge funds were net buyers of CRSP (83 opened a new position, 187 added to an existing one), while 200 reduced or exited (124 trimmed, 76 sold completely) — a 57% buyer ratio, indicating a slight buying edge. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 38% of total institutional value in CRSP is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +7 funds (more new holders than closures). Total institutional holders: 492.

Hedge Fund Ownership: CRSP

How many hedge funds hold CRSP — quarterly history vs. share price
Quarterly hedge fund ownership of CRSP vs. share price

Market Analysis: CRSP

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CRSP

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Crispr Therapeutics AG (CRSP) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CRSP has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 74d ago
CRSP
+4.7%
XLV
+4.9%

CRSP outperformed XLV by -0.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 29d ago
CRSP
+2.9%
XLV
+6.0%

Since the filing became public, CRSP outperformed XLV by -3.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

40 top-rated funds 4 high-conviction
Consensus
7.0
/ 10
breadth
×
Elite
3.6
/ 10
conviction
Hedge Fund Positioning: CRSP
489 + Investors

Track Smart Money conviction in CRSP. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 489 485 0.82%
13F Shares 80M 81M -0.66%
Total Value $3.65B $4.26B -14.28%
New Positions 82 97 -15
Increased Positions 176 152 +24
Closed Positions 78 58 +20
Reduced Positions 118 130 -12
Total Calls 22 22 -
Total Puts 12 14 -14.29%
PUT/CALL Ratio 0.55 0.64 Bullish

Statistics: CRSP

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

489 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CRSP. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CRSP holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 GSK plc 25.57% 3,220,627 $153.2M
2 Sr One Capital Management, LP 10.59% 2,038,763 $97.0M
3 Versant Venture Management, LLC 5.01% 148,831 $7.1M
4 ARK Investment Management LLC 4.19% 11,313,623 $538.2M
5 NEA Management Company, LLC 2.86% 1,058,570 $50.4M
6 EcoR1 Capital, LLC 2.80% 1,389,276 $66.1M
7 Green Alpha Advisors, LLC 2.67% 57,022 $2.7M
8 IQ EQ FUND MANAGEMENT (IRELAND) Ltd 1.45% 400,877 $19.1M
9 Deuterium Capital Management, LLC 1.38% 25,000 $1.2M
10 Monashee Investment Management LLC 1.29% 50,000 $2.4M
11 Amova Asset Management Americas, Inc. 1.25% 1,853,875 $88.2M
12 Orbis Allan Gray Ltd 1.23% 6,106,011 $290.5M
13 Nano Cap New Millennium Growth Fund L P 0.91% 20,500 $975K
14 Diadema Partners LP 0.86% 106,300 $5.1M
15 Baker Chad R 0.84% 93,300 $4.4M
16 Kassira Wealth Management LLC 0.69% 15,789 $751K
17 West Family Investments, Inc. 0.59% 35,500 $1.7M
18 Slow Capital, Inc. 0.56% 91,223 $4.3M
19 Jacobs Equity LLC 0.49% 11,590 $551K
20 Farrow Financial, Inc. 0.46% 16,979 $808K
21 Bouvel Investment Partners, LLC 0.45% 32,519 $1.5M
22 Privium Fund Management B.V. 0.42% 42,874 $2.0M
23 Affinity Asset Advisors, LLC 0.37% 150,000 $7.1M
24 Generali Investments Towarzystwo Funduszy Inwestycyjnych 0.37% 15,000 $714K
25 Himension Capital (singapore) PTE. LTD. 0.34% 92,481 $4.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Crispr Therapeutics AG (CRSP)

What does the Smart Money Trend signal show for CRSP?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added CRSP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CRSP?

Slight buying edge — 57% buying: Last quarter: 270 funds bought or added vs 200 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CRSP holders?

Strong quality — 38% AUM from major funds: 55 of 492 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CRSP?

55% of holders stayed for 2+ years: 269 out of 492 hedge funds have held CRSP for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Crispr Therapeutics AG (CRSP) following the 2026 Q1 hedge fund 13F filings?

As of today, CRSP has moved +2.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -3.1%. Since the quarter end (March 31, 2026), CRSP has gained +4.7% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →